340 related articles for article (PubMed ID: 36004816)
1. Natriuretic peptide pathways in heart failure: further therapeutic possibilities.
Sangaralingham SJ; Kuhn M; Cannone V; Chen HH; Burnett JC
Cardiovasc Res; 2023 Feb; 118(18):3416-3433. PubMed ID: 36004816
[TBL] [Abstract][Full Text] [Related]
2. Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation.
Ma X; Iyer SR; Ma X; Reginauld SH; Chen Y; Pan S; Zheng Y; Moroni DG; Yu Y; Zhang L; Cannone V; Chen HH; Ferrario CM; Sangaralingham SJ; Burnett JC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239899
[TBL] [Abstract][Full Text] [Related]
3. Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.
Ichiki T; Huntley BK; Sangaralingham SJ; Burnett JC
JACC Heart Fail; 2015 Sep; 3(9):715-23. PubMed ID: 26362447
[TBL] [Abstract][Full Text] [Related]
4. Left ventricular assist device support reverses altered cardiac expression and function of natriuretic peptides and receptors in end-stage heart failure.
Kuhn M; Voss M; Mitko D; Stypmann J; Schmid C; Kawaguchi N; Grabellus F; Baba HA
Cardiovasc Res; 2004 Nov; 64(2):308-14. PubMed ID: 15485690
[TBL] [Abstract][Full Text] [Related]
5. Characterization and functional expression of the natriuretic peptide system in human lens epithelial cells.
Cammarata PR; Braun B; Dimitrijevich SD; Pack J
Mol Vis; 2010 Apr; 16():630-8. PubMed ID: 20700369
[TBL] [Abstract][Full Text] [Related]
6. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.
Dickey DM; Potter LR
J Mol Cell Cardiol; 2011 Jul; 51(1):67-71. PubMed ID: 21459096
[TBL] [Abstract][Full Text] [Related]
7. Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications.
Ichiki T; Schirger JA; Huntley BK; Brozovich FV; Maleszewski JJ; Sandberg SM; Sangaralingham SJ; Park SJ; Burnett JC
J Mol Cell Cardiol; 2014 Oct; 75():199-205. PubMed ID: 25117468
[TBL] [Abstract][Full Text] [Related]
8. Natriuretic peptide system in the human retina.
Rollín R; Mediero A; Roldán-Pallarés M; Fernández-Cruz A; Fernández-Durango R
Mol Vis; 2004 Jan; 10():15-22. PubMed ID: 14737067
[TBL] [Abstract][Full Text] [Related]
9. Arg13 of B-type natriuretic Peptide reciprocally modulates binding to guanylyl cyclase but not clearance receptors.
Dickey DM; Barbieri KA; McGuirk CM; Potter LR
Mol Pharmacol; 2010 Sep; 78(3):431-5. PubMed ID: 20530652
[TBL] [Abstract][Full Text] [Related]
10. The natriuretic peptides in heart failure: diagnostic and therapeutic potentials.
Chen HH; Burnett JC
Proc Assoc Am Physicians; 1999; 111(5):406-16. PubMed ID: 10519161
[TBL] [Abstract][Full Text] [Related]
11. Molecular physiology of natriuretic peptide signalling.
Kuhn M
Basic Res Cardiol; 2004 Mar; 99(2):76-82. PubMed ID: 14963665
[TBL] [Abstract][Full Text] [Related]
12. Natriuretic peptides and therapeutic applications.
Lee CY; Burnett JC
Heart Fail Rev; 2007 Jun; 12(2):131-42. PubMed ID: 17440808
[TBL] [Abstract][Full Text] [Related]
13. Molecular and genetic aspects of guanylyl cyclase natriuretic peptide receptor-A in regulation of blood pressure and renal function.
Pandey KN
Physiol Genomics; 2018 Nov; 50(11):913-928. PubMed ID: 30169131
[TBL] [Abstract][Full Text] [Related]
14. Atrial Natriuretic Peptide - Old But New Therapeutic in Cardiovascular Diseases.
Ichiki T; Burnett JC
Circ J; 2017 Jun; 81(7):913-919. PubMed ID: 28552863
[TBL] [Abstract][Full Text] [Related]
15. The natriuretic peptides BNP and CNP increase heart rate and electrical conduction by stimulating ionic currents in the sinoatrial node and atrial myocardium following activation of guanylyl cyclase-linked natriuretic peptide receptors.
Springer J; Azer J; Hua R; Robbins C; Adamczyk A; McBoyle S; Bissell MB; Rose RA
J Mol Cell Cardiol; 2012 May; 52(5):1122-34. PubMed ID: 22326431
[TBL] [Abstract][Full Text] [Related]
16. The renal and cardiovascular effects of natriuretic peptides.
Wong PC; Guo J; Zhang A
Adv Physiol Educ; 2017 Jun; 41(2):179-185. PubMed ID: 28377431
[TBL] [Abstract][Full Text] [Related]
17. Genetic variation in the natriuretic peptide system and heart failure.
Lanfear DE
Heart Fail Rev; 2010 May; 15(3):219-28. PubMed ID: 18850266
[TBL] [Abstract][Full Text] [Related]
18. Presence and biological activity of C-type natriuretic peptide-dependent guanylate cyclase-coupled receptor in the penile corpus cavernosum.
Kim SZ; Kim SH; Park JK; Koh GY; Cho KW
J Urol; 1998 May; 159(5):1741-6. PubMed ID: 9554404
[TBL] [Abstract][Full Text] [Related]
19. Guanylyl cyclase / atrial natriuretic peptide receptor-A: role in the pathophysiology of cardiovascular regulation.
Pandey KN
Can J Physiol Pharmacol; 2011 Aug; 89(8):557-73. PubMed ID: 21815745
[TBL] [Abstract][Full Text] [Related]
20. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart.
Dickey DM; Flora DR; Bryan PM; Xu X; Chen Y; Potter LR
Endocrinology; 2007 Jul; 148(7):3518-22. PubMed ID: 17412809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
